Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2015 14:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium

Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients Median Progression-Free Survival of 6.6 Months in Tumor Notch3 High Patients and 5.6 Months in...
January 15, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Enrolls First Biomarker-Selected Patient in Expansion Stage of Anti-Notch1 Phase 1a Trial in Solid Tumors

REDWOOD CITY, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 13, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Clinical Data and Biomarker Analysis for Tarextumab at the 2015 Gastrointestinal Cancer Symposium

REDWOOD CITY, Calif., Jan. 13, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 12, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance

Begins 2015 with $232 Million in Cash Potential Milestones from Existing Partnerships in 2015/2016 Projected at Over $150 Million REDWOOD CITY, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) --...
January 07, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
January 05, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody

REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
December 01, 2014 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Begins Patient Dosing in Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer

REDWOOD CITY, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
November 21, 2014 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents New Clinical and Biomarker Data From Its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium

Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer Patient-Derived Preclinical and Clinical Data Support...
November 20, 2014 16:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
November 19, 2014 07:50 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium

BARCELONA, Spain and REDWOOD CITY, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem...